BofA reinstated coverage of AbbVie (ABBV) with a Neutral rating and $191 price target AbbVie is a relatively “quiet” stock with durable long-term growth, but the “problem” is that this seems discounted in its already above-average valuation, the analyst tells investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie to present results from two clinical trials of epcoritamab
- AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial
- AbbVie announces updated results from Phase 1b/2 EPCORE NHL-2 trial
- AbbVie downgraded to Neutral from Outperform at Daiwa
- Alector downgraded to Underperform at BofA after Alzheimer’s trial miss